Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Lidds

Related articles:
2/28/2023 7:03:46 AM - LIDDS: Setting sail - Redeye - Redeye revisits LIDDS following a change of analyst, a change of company CEO, and the outcome of a newly conducted rights issue. We endorse the company’s robust new focus on the business development of its portfolio, which should establish LIDDS in an encouraging position to seal a licensing deal in 2023.
12/19/2022 9:17:32 AM - LIDDS: Announces rights issue - Redeye - Redeye comments on LIDDS’ announcement of the proposed decision on a rights issue to strengthen the company’s financial position. In case of full subscription, the company has the potential to receive net cash of approximately SEKm39.9. We also adjust our base case to reflect the related dilution of the rights issue.
11/29/2022 8:12:51 AM - LIDDS: Steering the ship - Redeye - Redeye comments on LIDDS Q3’22 report. Anders Månsson, who succeeded Nina Herne as CEO of LIDDS in September 2022 provided a glimpse of LIDDS’ business strategy ahead. We also adjust our base case to reflect the refinancing planned in the first quarter of 2023.
8/26/2022 5:46:25 AM - Lidds Q2: Moving forward - Redeye - Redeye comments on LIDDS Q2’22 report. The company advances its projects, in particular with regard to nanodotax and nanoimod. The collaboration with Johnson & Johnson has moved into the next phase and LIDDS’ leading project Liproca Depot is currently being prepared for a clinical Phase III trial. We will return with a research update, where we will review our financial forecasts and fair value range.
7/15/2022 9:20:26 AM - Rhovacs vd säger upp sig efter misslyckade studien för prostatabehandling, blir ny vd på Lidds (uppdatering) - (Uppdatering avser att Månsson blir ny vd för Lidds)
6/13/2022 4:40:59 AM - Börsveckan ger köpråd för Wallenstam, Intervacc och Lidds - Börsveckan ger köpråd för Wallenstam, Intervacc och Lidds i den senaste utgåvan. Tidningen ger rådet avvakta för Godsinlösen, Trianon, Cibus och Stendörren.
5/27/2022 5:52:40 AM - Lidds Q1: Strengthening the pipeline - Redeye - Redeye maintains its positive view of LIDDS after the Q1 report. The company continues to invest in its pipeline and advance its projects, in particular the promising nanodotax, and the formulation with a TLR9 agonist. The collaboration with Johnson&Johnson continues, which is a validation of the NanoZolid platform. We see significant potential in LIDDS' immunotherapy projects and think that the company has laid a strong foundation for the future.
3/15/2022 7:07:59 AM - Lidds: Capital Market Day - Redeye - LIDDS' CEO Nina Herne presents at the company's Capital Market Day. Watch the replay from March 9.
2/24/2022 1:59:48 PM - Lidds Q4: Sharper focus and stronger team - Redeye - Redeye maintains its positive view and valuation of LIDDS after the report today. Sizeable revenues, sharper focus, and a stronger strategic approach to company development are setting the stage for a successful 2022.
2/23/2022 10:55:45 AM - Lidds: Convertables agreement, a temporary solution - Redeye - Redeye views the secured financing as a positive step but sees risks with the convertibles agreement putting downward pressure on the share price, over time.
2/22/2022 6:43:39 AM - Lidds: Next step for docetaxel candidate - Redeye - Redeye sees increased pipeline value in a prospective validation of the efficacy of LIDDS' drug candidate with docetaxel. Documented efficacy, especially in combination with immunotherapies, is an important basis for attracting and negotiating with prospective licensing partners.
1/18/2022 6:46:33 AM - LIDDS: Reimagining drug delivery - Redeye - In this update, we revisit LIDDS and take a deeper look at the company’s new vision and strategy, and NanoZolid®’s potential. We argue that the platform and the new focus area of immuno-oncology present a large opportunity and that the management has the capabilities and motivation to take advantage of it. We analyse the clinical data, the competition, the industry dynamics and present an updated valuation with a new target price.
1/12/2022 12:59:58 PM - Lidds: Validation of NanoZolid - Redeye - Redeye sees the successful completion of stage one of LIDDS' collaboration with Johnson & Johnson, as well as the decision to continue, as a validation of the NanoZolid platform.
11/23/2021 9:45:10 AM - Lidds Q3: Sharper vision and pipeline progress - Redeye - Redeye maintains its positive view on LIDDS after the report today. The management and the board have defined a sharper vision and a clearer strategic direction of the company, also with the goal to put a sustainable financing solution in place. The projects are advancing according to plan, with a stronger focus on immunooncology. LIDDS is playing for the long run.
10/5/2021 6:39:52 AM - Lidds: Phase I with docetaxel successfully completed - Redeye - Redeye maintains a positive view on LIDDS after the successful completion of phase I safety and tolerability study with NanoZolid combined with docetaxel. The drug candidate shows signs of efficacy and it is on a path to become an important asset for the company. We also welcome the culture and strategy change initiated by the new CEO.
8/26/2021 11:28:05 AM - Lidds Q2: Building value in the pipeline - Redeye - Redeye maintains a positive view on LIDDS after today's Q2 report. The company is building value in its portfolio and is supported by a strong global trend that will bring cancer treatment to the top of the healthcare priority list in the coming years, in our view.
6/3/2021 12:33:41 PM - Lidds: Stronger ownership and finances - Redeye - Redeye is positive to LIDDS' announced capital raise through a directed share issue. It allows the company to develop its projects in cancer therapy and immuno-oncology, validates investor interest and brings new shareholders on board.
5/18/2021 9:00:50 AM - Lidds Q1: Focus on out-licensing - Redeye - Redeye maintains a positive view of LIDDS and the company's capability to execute its out-licensing strategy and develop its clinical program based on the Nanozolid-platform, after the Q1 report today.
3/31/2021 5:56:52 AM - Lidds: Proceding as planned with the phase III study - Redeye - Redeye maintains its positive view on LIDDS after today's announcement that a multi-centre phase III clinical study will be conducted Liproca® Depot. We did not consider an expedient conditional approval in China very likely and believe that solid phase III data will strengthen the case for intratumoral treatment. We see the current stock price decline as an overreaction, as phase III study was the original plan and management has demonstrated an ability to deliver on its strategy.
3/2/2021 2:07:17 PM - Lidds rusar 25 procent på avtal med J&J - Läkemedelsbolaget Lidds rusar under tisdagseftermiddagen på beskedet om att bolaget tecknat avtal med Johnson & Johnson. Bolagen ska tillsammans utveckla en ny cancerbehandling som baseras på Lidds teknikplattform Nanozolid inom en ännu inte offentlig indikation.
12/22/2020 7:59:11 AM - Lidds tänker ansöka om notering på Stockholmsbörsens huvudlista - Life science-bolaget Lidds tänker ansöka om en notering på Stockholmsbörsens huvudlista under nästa år, enligt ett pressmeddelande. Bolaget är idag noterat på Nasdaq First North.